Sector News

AstraZeneca, its new HQ delayed and way over budget, weighs a construction partner swap: report

August 21, 2018
Life sciences

AstraZeneca has been planning to move thousands of employees into a new headquarters for years, but its ongoing construction project has suffered from repeated delays and cost overruns. Now, the company is making moves to sideline its chief contractor to hire another, according to the Construction Enquirer.

The drug giant is in talks to replace Skanska on the project, the publication reports. AstraZeneca declined to comment and Skanska didn’t immediately respond to a request for comment. A source told the Construction Enquirer some of the delay has been caused by a high water table on the site that required “a lot of remedial work,” plus design and other issues.

The move comes after an announcement last year that the HQ and tandem R&D facility will cost more than £500 million, significantly more than the original budget of £330 million. The drugmaker unveiled its HQ plan back in 2013 and hoped to start moving in 2016.

In March, the Cambridge News reported the project isn’t expected to be complete until May 2019. At the time, AstraZeneca and Skanska petitioned for longer working hours because the project suffered from an “overheated” construction market that left them unable to find enough contractors to complete the job on time, according to the report.

Even so, an AZ representative said the drugmaker plans to start a phased move-in by the end of 2018.

Aside from those issues, some excess cost could be attributed to new capabilities added to the R&D labs after the buildings were first conceived, such as robotics, a spokesperson previously told FierceBiotech.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.